Last reviewed · How we verify
adjuvant temozolomide (TMZ)
Temozolomide is an alkylating agent that works by interfering with DNA replication and transcription, thereby inhibiting cancer cell growth.
Temozolomide is an alkylating agent that works by interfering with DNA replication and transcription, thereby inhibiting cancer cell growth. Used for Glioblastoma multiforme, Anaplastic astrocytoma.
At a glance
| Generic name | adjuvant temozolomide (TMZ) |
|---|---|
| Sponsor | Alliance for Clinical Trials in Oncology |
| Drug class | alkylating agent |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Temozolomide is a prodrug that is converted into its active form, MTIC, which then methylates DNA, leading to DNA damage and apoptosis in rapidly dividing cells. This mechanism is particularly effective against glioblastoma cells, which have a high rate of proliferation.
Approved indications
- Glioblastoma multiforme
- Anaplastic astrocytoma
Common side effects
- Myelosuppression
- Nausea and vomiting
- Fatigue
- Headache
- Dizziness
Key clinical trials
- Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme (PHASE2, PHASE3)
- Pembrolizumab and Standard Therapy in Treating Patients With Glioblastoma (PHASE2)
- DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult Glioblastoma (GBM) (PHASE2)
- Phase 0/2 PD-Trigger Study of BGB-58067 in Newly Diagnosed Glioblastoma Patients With MTAP-Deleted Tumors (EARLY_PHASE1)
- Adjuvant Temozolomide ± 5-Aminolevulinic Acid + Low Intensity Diffuse Ultrasound Sonodynamic Therapy System for Newly Diagnosed Glioblastoma (PHASE2)
- Treatment Intensification With Temozolomide in Adults With a Glioblastoma (PHASE3)
- Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM (PHASE1)
- Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) for the Treatment of Patients With Progressing Metastatic Neuroendocrine Carcinomas (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- adjuvant temozolomide (TMZ) CI brief — competitive landscape report
- adjuvant temozolomide (TMZ) updates RSS · CI watch RSS
- Alliance for Clinical Trials in Oncology portfolio CI